Use of an LTB4 antagonist for the treatment or prevention of diseases caused by increased expression of mucin genes

The invention relates to the use of a LTB antagonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment and/or prevention of diseases caused by increased expression of mucin genes in the bronchial or gastrointestinal epithelium. Medicaments and pharmaceutical kits comprising an LTBantagonist of formula (I) a tautomer thereof or a pharmaceutically acceptable salt thereof, and methods of treating or preventing cystic fibrosis, diseases caused by increased expression of mucin genes in the bronchial or gastrointestinal epithelium, or hyperplasia of goblet cells induced by toxins of products of pathogenic bacteria in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of an LTBantagonist of formula (I).